Bladder Cancer Trial, Recruiting NCT06735287 Sponsor: The First Affiliated Hospital with Nanjing Medical University Condition: Bladder Cancer
Back to Bladder Cancer

Bladder Cancer Trial, Recruiting

NCT06735287
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a large bladder cancer that has not grown into the muscle wall of the bladder (the tumor is 5 cm or larger, there are 3 or fewer tumors, and imaging or biopsy results meet specific criteria).
  • Your heart, bone marrow, liver, and kidneys are working well enough to handle the treatments involved (based on specific blood test results — confirm with trial site).
  • You have no severe blood disorders or major organ problems (confirm with trial site).
  • You are generally healthy or only mildly affected by your illness, based on a standard fitness scale (rated 0 or 1 out of 4).
  • You have no history of any other cancer.
  • You are able to receive a standard bladder wash treatment (using a drug called mitomycin C) after your bladder surgery.
  • You are between 18 and 79 years old.
  • You are willing to take part, have signed a consent form, and are able to attend regular follow-up appointments.

Who may not be able to join:

  • Your pre-surgery scan results show a score of 3 or higher on a specific bladder imaging scale (VI-RADS ≥ 3).
  • Your post-surgery tissue results show a cancer type other than the most common bladder cancer type, or show that the cancer has grown into the bladder muscle or deeper.
  • You have cancer that has spread to your lymph nodes or other parts of your body.
  • You have a known allergy or strong reaction to any of the treatment drugs used in this trial.
  • You have an autoimmune disease (a condition where your immune system attacks your own body).
  • Your doctor feels that any other health condition you have could put you at risk or prevent you from completing the study (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +8615151211913

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 December 2024
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

recurrence free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov